External and intrinsic anchoring in nematic liquid crystals: A Monte Carlo study

We present a Monte Carlo study of external surface anchoring in nematic cells with partially disordered solid substrates, as well as of intrinsic anchoring at free nematic interfaces. The simulations are based on the simple hexagonal lattice model with a spatially anisotropic intermolecular potential. We estimate the corresponding extrapolation length $b$ by imposing an elastic deformation in a hybrid cell-like nematic sample. Our estimates for $b$ increase with increasing surface disorder and are essentially temperature--independent. Experimental values of $b$ are approached only when both the coupling of nematic molecules with the substrate and the anisotropy of nematic--nematic interactions are weak.Comment: Revisions primarily in section I

A Note on Non-equilibrium Work Fluctuations and Equilibrium Free Energies

We consider in this paper, a few important issues in non-equilibrium work fluctuations and their relations to equilibrium free energies. First we show that Jarzynski identity can be viewed as a cumulant expansion of work. For a switching process which is nearly quasistatic the work distribution is sharply peaked and Gaussian. We show analytically that dissipation given by average work minus reversible work $W_R$, decreases when the process becomes more and more quasistatic. Eventually, in the quasistatic reversible limit, the dissipation vanishes. However estimate of $p$ - the probability of violation of the second law given by the integral of the tail of the work distribution from $-\infty$ to $W_R$, increases and takes a value of $0.5$ in the quasistatic limit. We show this analytically employing Gaussian integrals given by error functions and Callen-Welton theorem that relates fluctuations to dissipation in process that is nearly quasistatic. Then we carry out Monte Carlo simulation of non-equilibrium processes in a liquid crystal system in the presence of an electric field and present results on reversible work, dissipation, probability of violation of the second law and distribution of workComment: 15 pages, 4 figure

Long-term efficacy and safety of brodalumab in the treatment of psoriasis : 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial

Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial. Patients received ustekinumab through week 52 followed by brodalumab 210 mg every 2 weeks, continuous brodalumab 210 mg every 2 weeks, or any dose of brodalumab. Efficacy data were reported through 120 weeks by using observed data, last observation carried forward, and nonresponder imputation analyses. Of patients who received brodalumab 210 mg every 2 weeks, 84.4%, 75.6%, and 61.1% achieved 75%, 90%, and 100% improvement from baseline in Psoriasis Area and Severity Index at 120 weeks (observed data analysis), respectively. Patients who received brodalumab 210 mg every 2 weeks after receiving ustekinumab through 52 weeks achieved a similar skin clearance response as patients who received continuous brodalumab 210 mg every 2 weeks. Safety through 120 weeks was comparable to that of the blinded study periods. A large number of discontinuations toward the end of the study (31% in the final 6 months) were due to early termination and led to differences between observed data and nonresponder imputation results. Brodalumab is well tolerated and showed robust efficacy for more than 2 years

A new hard-particle model for anisotropic fluids

We report a new hard-particle model system consisting of hard cylinders, we have determined the geometrical conditions that let us know whether or not two given cylinders overlap. In addition we have carried out Monte Carlo simulations sampling the canonical ensemble on this system, the numerical results indicate that this system exhibits mesomorphic behaviour

O(N) and RP^{N-1} Models in Two Dimensions

I provide evidence that the 2D $RP^{N-1}$ model for $N \ge 3$ is equivalent to the $O(N)$-invariant non-linear $\sigma$-model in the continuum limit. To this end, I mainly study particular versions of the models, to be called constraint models. I prove that the constraint $RP^{N-1}$ and $O(N)$ models are equivalent for sufficiently weak coupling. Numerical results for their step-scaling function of the running coupling $\bar{g}^2= m(L) L$ are presented. The data confirm that the constraint $O(N)$ model is in the samei universality class as the $O(N)$ model with standard action. I show that the differences in the finite size scaling curves of $RP^{N-1}$i and $O(N)$ models observed by Caracciolo et al. can be explained as a boundary effect. It is concluded, in contrast to Caracciolo et al., that $RP^{N-1}$ and $O(N)$ models share a unique universality class.Comment: 14 pages (latex) + 1 figure (Postscript) ,uuencode

Topological transition in a two-dimensional model of liquid crystal

Simulations of nematic-isotropic transition of liquid crystals in two dimensions are performed using an O(2) vector model characterised by non linear nearest neighbour spin interaction governed by the fourth Legendre polynomial $P\_4$. The system is studied through standard Finite-Size Scaling and conformal rescaling of density profiles of correlation functions. A topological transition between a paramagnetic phase at high temperature and a critical phase at low temperature is observed. The low temperature limit is discussed in the spin wave approximation and confirms the numerical results

Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis

BACKGROUND: Therapies specifically targeting nonhistaminergic pruritus are largely lacking. Difelikefalin (DFK) has been found to reduce itch in various chronic pruritic conditions, including atopic dermatitis (AD). OBJECTIVE: We sought to investigate the ability of DFK to impact scratching behavior, inflammatory mediators, and neuronal signaling in a murine model of AD. METHODS: The ears of C57BL/6 mice were topically treated with MC903 for 12 consecutive days to induce AD-like inflammation and itch. Before MC903 treatment, mice were treated with either DFK (0.5 mg/kg, intraperitoneal injection twice daily) or vehicle (saline). Skin ear thickness, histological analysis, flow cytometry, RNA-sequencing, and differential gene expression analyses of mouse ear skin were used to examine the effect of DFK on skin inflammation. Scratching behavior was quantified to measure itch behavior in mice that were topically treated with MC903 for 6 consecutive days; then, mice received a single injection of either DFK (1.0 mg/kg, intraperitoneal injection) or saline. Calcium imaging and single-cell RNA-sequencing were used in mouse dorsal root ganglia neurons to determine the size of the neurons activated with DFK treatment. Statistical significance was determined by Mann-Whitney test, unless otherwise noted. RESULTS: DFK rapidly suppressed itch without altering AD-like skin inflammation in MC903 (calcipotriol)-treated mice. In vitro Ca CONCLUSIONS: These studies support a potential neuromodulatory role of DFK for reducing itch associated with AD in mice

High-Temperature series for the RPn−1RP^{n-1} lattice spin model (generalized Maier-Saupe model of nematic liquid crystals) in two space dimensions and with general spin dimensionality n

High temperature series expansions of the spin-spin correlation functions of the RP^{n-1} spin model on the square lattice are computed through order beta^{8} for general spin dimensionality n. Tables are reported for the expansion coefficients of the energy per site, the susceptibility and the second correlation moment.Comment: 6 pages, revtex, IFUM 419/FT, 2 figures not include

Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases

Fluticasone propionate - the first carbothioate corticosteroid - has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid